Assessment of lung function in successfully treated tuberculosis reveals high burden of ventilatory defects and COPD.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
01
2019
accepted:
08
05
2019
entrez:
24
5
2019
pubmed:
24
5
2019
medline:
30
1
2020
Statut:
epublish
Résumé
Burden, phenotype and risk-factors of lung function defects in successfully treated tuberculosis cases are unclear. We performed spirometry with bronchodilators in new drug-sensitive adult (≥18 years) pulmonary tuberculosis cases during the 12 months following successful treatment in India. Airflow obstruction was defined as pre-bronchodilator FEV1/FVC<5th percentile of Global Lung Initiative mixed-ethnicity reference (lower limit of normal [LLN]). Chronic obstructive pulmonary disease (COPD) was defined as post-bronchodilator FEV1/FVC<LLN among participants with obstruction. Restrictive spirometry pattern was defined as FVC<LLN among participants without obstruction. Multivariable logistic and linear regression was used to identify risk-factors for obstruction, restriction and low lung function despite successful treatment. Of the 172 participants included in the analysis, 82 (48%) were female, 22 (13%) had diabetes and 34 (20%) ever-smoked with a median (IQR) exposure of 3.5 (0.2-9.9) pack-years. Median (IQR) age and body-mass index (BMI) at enrollment was 32 (23-39) years and 18.1 (16.0-20.5) kg/m2 respectively. Airflow obstruction was detected in 42 (24%) participants; of whom 9 (21%) responded to short-acting bronchodilators and 25 (56%) had COPD; and was associated with duration of illness prior to treatment (aOR = 1.32 per 30-days, 95%CI 1.04-1.68, p = 0.02). A restrictive spirometry pattern was detected in 89 (52%) participants and was associated with female sex (aOR = 3.73, 95%CI 1.51-9.17, p = 0.004) and diabetes (aOR = 4.06, 95%CI 1.14-14.42, p = 0.03). Higher HbA1c at treatment initiation was associated with greater odds of a restrictive spirometry pattern (aOR = 1.29 per unit higher HbA1c, 95%CI 1.04 to 1.60, p = 0.02). We found a high burden of lung function defects and COPD in tuberculosis cases who successfully completed treatment. Screening for chronic lung diseases following treatment and linkage to respiratory health clinics should be included in the routine management plan of all tuberculosis cases in India, regardless of conventional COPD risk-factors such as older age and smoking.
Sections du résumé
BACKGROUND
Burden, phenotype and risk-factors of lung function defects in successfully treated tuberculosis cases are unclear.
METHODS
We performed spirometry with bronchodilators in new drug-sensitive adult (≥18 years) pulmonary tuberculosis cases during the 12 months following successful treatment in India. Airflow obstruction was defined as pre-bronchodilator FEV1/FVC<5th percentile of Global Lung Initiative mixed-ethnicity reference (lower limit of normal [LLN]). Chronic obstructive pulmonary disease (COPD) was defined as post-bronchodilator FEV1/FVC<LLN among participants with obstruction. Restrictive spirometry pattern was defined as FVC<LLN among participants without obstruction. Multivariable logistic and linear regression was used to identify risk-factors for obstruction, restriction and low lung function despite successful treatment.
RESULTS
Of the 172 participants included in the analysis, 82 (48%) were female, 22 (13%) had diabetes and 34 (20%) ever-smoked with a median (IQR) exposure of 3.5 (0.2-9.9) pack-years. Median (IQR) age and body-mass index (BMI) at enrollment was 32 (23-39) years and 18.1 (16.0-20.5) kg/m2 respectively. Airflow obstruction was detected in 42 (24%) participants; of whom 9 (21%) responded to short-acting bronchodilators and 25 (56%) had COPD; and was associated with duration of illness prior to treatment (aOR = 1.32 per 30-days, 95%CI 1.04-1.68, p = 0.02). A restrictive spirometry pattern was detected in 89 (52%) participants and was associated with female sex (aOR = 3.73, 95%CI 1.51-9.17, p = 0.004) and diabetes (aOR = 4.06, 95%CI 1.14-14.42, p = 0.03). Higher HbA1c at treatment initiation was associated with greater odds of a restrictive spirometry pattern (aOR = 1.29 per unit higher HbA1c, 95%CI 1.04 to 1.60, p = 0.02).
CONCLUSION
We found a high burden of lung function defects and COPD in tuberculosis cases who successfully completed treatment. Screening for chronic lung diseases following treatment and linkage to respiratory health clinics should be included in the routine management plan of all tuberculosis cases in India, regardless of conventional COPD risk-factors such as older age and smoking.
Identifiants
pubmed: 31120971
doi: 10.1371/journal.pone.0217289
pii: PONE-D-19-01394
pmc: PMC6532904
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0217289Subventions
Organisme : FIC NIH HHS
ID : D43 TW009340
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009574
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI097494
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069465
Pays : United States
Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Lancet. 2007 Sep 1;370(9589):741-50
pubmed: 17765523
PLoS One. 2015 Oct 23;10(10):e0141230
pubmed: 26496500
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Int J Tuberc Lung Dis. 2019 Feb 1;23(2):203-211
pubmed: 30808453
PLoS Med. 2008 Jul 15;5(7):e152
pubmed: 18630984
Lancet. 2010 May 22;375(9728):1814-29
pubmed: 20488524
Eur Respir J. 2012 Jun;39(6):1343-53
pubmed: 22183479
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
Int J Obes (Lond). 2005 Sep;29(9):1055-62
pubmed: 15917843
Thorax. 2000 Jan;55(1):32-8
pubmed: 10607799
Am J Respir Crit Care Med. 2008 Feb 1;177(3):253-60
pubmed: 18006882
PLoS One. 2013 Nov 29;8(11):e80302
pubmed: 24312209
N Engl J Med. 2008 Oct 9;359(15):1543-54
pubmed: 18836213
PLoS One. 2012;7(5):e37978
pubmed: 22662259
Lancet. 2009 Aug 29;374(9691):733-43
pubmed: 19716966
Lung. 2011 Aug;189(4):311-21
pubmed: 21567165
Diabetes Care. 2014 Feb;37(2):389-95
pubmed: 24026562
Int J Tuberc Lung Dis. 2009 Dec;13(12):1500-6
pubmed: 19919767
Diabetes Care. 2010 Jan;33(1):55-60
pubmed: 19808918
Indian J Chest Dis Allied Sci. 2006 Jan-Mar;48(1):23-9
pubmed: 16482948
BMJ Open. 2016 Feb 25;6(2):e010542
pubmed: 26916698
Int J Tuberc Lung Dis. 2015 May;19(5):589-95
pubmed: 25868029
Int J Tuberc Lung Dis. 2016 Jan;20(1):43-8
pubmed: 26688527
Eur Respir J. 2007 Dec;30(6):1180-5
pubmed: 17804445
Chest. 2007 Nov;132(5):1591-8
pubmed: 17890471
Int J Tuberc Lung Dis. 2019 Feb 1;23(2):195-202
pubmed: 30808452
Am J Public Health. 2015 May;105(5):930-7
pubmed: 25790407
Respir Med. 2016 May;114:67-71
pubmed: 27109813
Glob Health Action. 2014 Nov 04;7:25326
pubmed: 25373414
Chest. 2007 Jun;131(6):1817-24
pubmed: 17400690
Respir Med. 1991 Sep;85 Suppl B:25-31; discussion 33-7
pubmed: 1759018
PLoS One. 2012;7(7):e41367
pubmed: 22848473
Eur Respir J. 2002 Mar;19(3):398-404
pubmed: 11936514
PLoS One. 2009;4(4):e5080
pubmed: 19352424
Lancet Glob Health. 2018 Dec;6(12):e1363-e1374
pubmed: 30219316
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Eur Respir J. 2015 Oct;46(4):1104-12
pubmed: 26113680
Am J Respir Crit Care Med. 2008 Aug 15;178(4):332-8
pubmed: 18511702
Eur Respir J. 2012 Jul;40(1):190-7
pubmed: 22183491
Indian J Tuberc. 2009 Jul;56(3):132-40
pubmed: 20349754
Eur Respir J. 1998 Aug;12(2):351-6
pubmed: 9727784
Lancet Respir Med. 2017 Sep;5(9):691-706
pubmed: 28822787
Int J Tuberc Lung Dis. 2004 Feb;8(2):211-7
pubmed: 15139450
Respir Res. 2008 Apr 04;9:31
pubmed: 18394165
Lancet. 2017 Dec 2;390(10111):2437-2460
pubmed: 29150201
Int J Infect Dis. 2015 Mar;32:138-46
pubmed: 25809770
Clin Epidemiol. 2014 Nov 13;6:405-21
pubmed: 25419160
Trop Med Int Health. 2010 Nov;15(11):1300-14
pubmed: 20958887
J Postgrad Med. 2014 Apr-Jun;60(2):123-9
pubmed: 24823509
Thorax. 2001 Nov;56(11):880-7
pubmed: 11641515
Chest. 2011 Oct;140(4):1055-1063
pubmed: 21972384
Respir Med. 2011 Jul;105(7):1095-8
pubmed: 21450445
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Chest. 2010 Mar;137(3):593-600
pubmed: 19820078
Chest. 2007 Nov;132(5):1608-14
pubmed: 17998360
Int J Tuberc Lung Dis. 2013 Jun;17(6):810-3
pubmed: 23676167
Chest. 2016 Jan;149(1):238-51
pubmed: 26356330
S Afr Med J. 2017 Apr 25;107(5):440-445
pubmed: 28492127
Clinics (Sao Paulo). 2011;66(4):549-56
pubmed: 21655745
Respir Med. 1989 May;83(3):195-8
pubmed: 2595036
Chest. 2008 Feb;133(2):343-9
pubmed: 17951621